Arbutus Biopharma Corporation
ABUS
$3.43
-$0.04-1.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -37.21% | 35.11% | 1.92% | -15.81% | -9.40% |
| Total Depreciation and Amortization | -7.04% | -7.24% | -8.94% | 4.09% | 6.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 410.70% | 1,114.37% | -14.18% | 81.95% | 4.43% |
| Change in Net Operating Assets | 284.30% | -115.40% | 26.11% | 168.88% | 76.82% |
| Cash from Operations | 30.60% | 40.35% | 4.81% | 25.84% | 29.32% |
| Capital Expenditure | -- | -- | 100.00% | 99.88% | 18.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.73% | -39.27% | -214.80% | 327.39% | -29.81% |
| Cash from Investing | -2.95% | -39.66% | -214.93% | 582.10% | -29.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -88.60% | -62.67% | 5.59% | 413.92% | 19.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -88.60% | -62.67% | 5.59% | 413.92% | 19.66% |
| Foreign Exchange rate Adjustments | 130.77% | -335.71% | -37.50% | -700.00% | -425.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -95.56% | -48.78% | -220.11% | 247.17% | 71.63% |